On November 4, BeiGene announced that the US Food and Drug Administration has accepted the new marketing license application for Baiyuze® combined with rituximab for priority review and approval, and is intended for use in adult first-time patients with mantle cell lymphoma. This application is based on the results of a critical MANGROVE phase 3 clinical study. The data shows that compared to standard immunochemotherapy regimens, this chemotherapy-free treatment plan is expected to significantly reduce patients' risk of disease progression or death.

On November 4, BeiGene announced that the US Food and Drug Administration has accepted the new marketing license application for Baiyuze® combined with rituximab for priority review and approval, and is intended for use in adult first-time patients with mantle cell lymphoma. This application is based on the results of a critical MANGROVE phase 3 clinical study. The data shows that compared to standard immunochemotherapy regimens, this chemotherapy-free treatment plan is expected to significantly reduce patients' risk of disease progression or death.